Recent media coverage about OvAware™

Posted: May 20, 2016

Dr. Dayan Goodenowe discusses the OvAware™ test for ovarian cancer in the following interviews and articles: Interview with John Gormley: Interview on CJME (at 5:20 in the clip): Saskatoon Home Page article: ( Genome […]

Read More

Phenomenome Discoveries Announces the Successful Validation of OvAware™, a simple blood test for the Early Detection of Ovarian Cancer

Posted: May 12, 2016

SASKATOON, May 12, 2016 /PRNewswire/ – Using its proprietary metabolomics technology, Phenomenome Discoveries Inc. had previously discovered that specific metabolic abnormalities were present in the blood of women suffering from ovarian cancer.  The company […]

Read More

Upcoming presentations and sales events

Posted: May 6, 2016

PDI is pleased to announce the following upcoming presentations and FTI sales process events: FTI marketing events – Asia: Tokyo, Japan – May 23rd Shanghai, China – May 25th Hong Kong, China – May 27th […]

Read More

PDI sales process announced

Posted: May 5, 2016

PDI is pleased to announce that the formal sales process has been approved (see information memorandum).  The assets of PDI have been divided into six groups (Diagnostic Testing Unit, Cancer Diagnostics, Neurological Diagnostics, Therapeutics, Laboratory, […]

Read More

Phenomenome Discoveries Inc. (PDI) to undergo a restructuring of its asset portfolio

Posted: March 11, 2016

Phenomenome Discoveries Inc. (PDI) was founded in 2000 based upon a novel biomarker discovery technology called non-targeted complex sample analysis that was invented by its founder, Dr. Dayan Goodenowe. Since its founding, with the […]

Read More